Plus deals involving Biocytogen, Neurocrine and Ona, Aeterna Zentaris/Ceapro, Teva/Biolojic Design, Pathos AI/Rain Oncology, Inhibitor Therapeutics/Johns Hopkins and more.

Emerging companies including Bliss Biopharmaceutical, Coherent Biopharma and WestGene Biopharma lifted China biotech funding from May to mid-June.

Reflecting on the latest batch of deals, Global Head Robert Urban discusses the progress J&J Innovation has made so far and the next steps as it launches its JLINX incubator.

Janssen gets option to Modern’s small-molecule candidates for rheumatoid arthritis that could address both the inflammatory and bone-damaging effects of the disease. An R&D exec says the compounds could be complementary to, or used in combination with, Remicade and Simponi, or as standalone RA therapies.